ImmunityBio (IBRX) Research & Development (2014 - 2026)

ImmunityBio (IBRX) has reported Research & Development for 13 consecutive years, with $600000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Research & Development changed 0.0% year-over-year to $600000.0; the TTM figure through Mar 2026 stood at $700000.0 (down 68.18% YoY), while the FY2024 annual figure was $2.3 million, up 15.0% from the prior year.
• Research & Development advanced to $600000.0 in Q1 2026 per IBRX's latest filing, from $100000.0 in the prior quarter.
• Across five years, Research & Development topped out at $79.3 million in Q1 2023 and bottomed at -$178.8 million in Q4 2023.
• Historically, Research & Development has averaged $16.9 million across 5 years, with a median of $700000.0 in 2024.
• Annual changes were most pronounced in 2023 — Research & Development sank 407.93% — and 2024, when it surged 100.34%.
• ImmunityBio's Research & Development stood at $58.1 million in 2022, then tumbled by 407.93% to -$178.8 million in 2023, then jumped by 100.34% to $600000.0 in 2024, then plunged by 83.33% to $100000.0 in 2025, then soared by 500.0% to $600000.0 in 2026.
• Business Quant data shows IBRX's Research & Development at $600000.0 in Q1 2026, $100000.0 in Q3 2025, and $600000.0 in Q1 2025.